Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
-- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Arcadia Biosciences, Inc.® ( Nasdaq: RKDA ) , a producer and ...
How this was made
The 30-second read
Why it matters
The quarterly results indicate operational stability and growth, supporting a cautiously optimistic outlook.
Market read
The news is relevant primarily to existing investors and sector analysts, with limited immediate impact on stock price.
What to watch
Potential upcoming product launches or regulatory developments could influence future performance but are not covered in this report.
Background
Arcadia Biosciences is a biotech company focusing on sustainable agriculture and food solutions.
Ticker impact
Primary focus of the news, as it reports quarterly financial results for Arcadia Biosciences.
Limited immediate impact on stock price; potential for moderate positive movement if results are viewed favorably.
Financial results are positive but already anticipated by the market; the modest cash decline is typical and does not indicate distress.
Market effects
Positive sentiment for the biotech and life sciences sectors, reflecting industry resilience.
Limited regional impact; company operates primarily in the U.S.
Minimal; company’s financials are not a major driver of global markets.
Counterpoint
Some investors might interpret the cash decline as a sign of increasing operational costs or investments, warranting caution.
Key entities
- CompanyArcadia Biosciences
Biotech firm specializing in agricultural solutions.



